Matinas BioPharma to start Part 2 study of MAT2203 for HIV-patients
Category: #healthcare  By Akshay Kedari  Date: 2020-02-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Matinas BioPharma to start Part 2 study of MAT2203 for HIV-patients

Matinas BioPharma, a renowned biopharmaceutical company, has reportedly announced that DSMB (Data Safety Monitoring Board) for the EnACT study has finished its planned review of initial tolerability and safety data from the Part 1 dose escalation phase and has also permitted continuation of enlistment in the Part 2 efficacy stage at 2g of MAT2203 daily, the biggest dose that was tested in Part 1.

The 2g dose would be tested in the second week initiation phase of treatment. Data from Part 1 revealed that MAT2203 was safe as well as well-tolerated throughout all of the three daily doses tested. The part 2 of the EnACT study would discover the usage of MAT2203 for initiation as well as maintenance therapy in HIV-patients diagnosed with cryptococcal meningitis, a serious infection of the brain and spinal column which is observed in individuals having an impaired immune system.

Theresa Matkovits Ph.D., chief development officer, Matinas, stated that the company is thrilled with its advancement in the EnACT trial. The company is looking forward for treating the first patient in Part 2 of the study in the coming weeks and is also anticipated to provide updates on the estimated progression from patient group to group across 2020.

David Boulware M.D., M.P.H, principal investigator of the trial and Prof of Medicine, University of Minnesota, stated that the forthcoming efficacy portion of the randomized clinical stage trial in individuals diagnosed with cryptococcal meningitis would allow for further assessment of the safety as well as efficacy of MAT2203.

Boulware further stated that if the efficacy phase is successful, an orally administered formulation of amphotericin could provide an oral as well as well-tolerated medication for severe fungal infections in these patients.

EnACT is a sequential cohort study as well as is an open-label trial, financially funded by the NIH (National Institutes of Health) with David Boulware as the principal investigator in partnership with Dr David Meya.

Source credit: https://www.matinasbiopharma.com/media/press-releases/detail/360/matinas-biopharma-announces-dsmb-approval-to-commence-part

 

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Biological E starts human trials of COVID-19 vaccine in India
Biological E starts human trials of COVID-19 vaccine in India
By Akshay Kedari

Biological E. Limited, an India-based vaccines and pharmaceutical company, has reportedly started ph...

Five Prime announces pre-clinical data of anti-CCR8 FPA157 program
Five Prime announces pre-clinical data of anti-CCR8 FPA157 program
By Akshay Kedari

Five Prime Therapeutics, Inc. has recently revealed the 1st pre-clinical data of the anti-CCR8 FPA15...

Opear reveals 2 promotions to boost patients’ access to healthcare
Opear reveals 2 promotions to boost patients’ access to healthcare
By Akshay Kedari

Opear MD, a membership-based app, has reportedly announced two promotions to improve affordability a...